A

Apollo Endosurgery Inc
F:HQ8F

Watchlist Manager
Apollo Endosurgery Inc
F:HQ8F
Watchlist
Price: 9.1 EUR 1.09%
Market Cap: €432.7m

Apollo Endosurgery Inc
Other Non-Cash Items

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Apollo Endosurgery Inc
Other Non-Cash Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Non-Cash Items CAGR 3Y CAGR 5Y CAGR 10Y
A
Apollo Endosurgery Inc
F:HQ8F
Other Non-Cash Items
$12.5m
CAGR 3-Years
N/A
CAGR 5-Years
40%
CAGR 10-Years
N/A
Boston Scientific Corp
NYSE:BSX
Other Non-Cash Items
$522m
CAGR 3-Years
-1%
CAGR 5-Years
77%
CAGR 10-Years
N/A
Edwards Lifesciences Corp
NYSE:EW
Other Non-Cash Items
$332.2m
CAGR 3-Years
14%
CAGR 5-Years
23%
CAGR 10-Years
32%
Stryker Corp
NYSE:SYK
Other Non-Cash Items
$586m
CAGR 3-Years
10%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Abbott Laboratories
NYSE:ABT
Other Non-Cash Items
$729m
CAGR 3-Years
-6%
CAGR 5-Years
-7%
CAGR 10-Years
4%
Intuitive Surgical Inc
NASDAQ:ISRG
Other Non-Cash Items
$730m
CAGR 3-Years
9%
CAGR 5-Years
16%
CAGR 10-Years
13%
No Stocks Found

Apollo Endosurgery Inc
Glance View

Market Cap
432.7m EUR
Industry
Health Care

Apollo Endosurgery, Inc. is a medical technology company, which focuses on the design, development, and commercialization of medical devices to advance gastrointestinal therapeutic endoscopy. The company is headquartered in West Lake Hills, Texas and currently employs 107 full-time employees. The company went IPO on 2005-04-21. The firm develops and distributes devices that are used by surgeons and gastroenterologists for various procedures related to gastrointestinal conditions including closure of gastrointestinal defects, managing gastrointestinal complications and the treatment of obesity. The firm's products include the OverStitch Endoscopic Suturing System, which enables advanced endoscopic procedures from within the Gastrointestinal tract, or endolumenally, by allowing physicians to suture, especially full-thickness, and secure the approximation of tissue. The X-Tack Endoscopic HeliX Tacking System is a suture-based device designed specifically for closing and healing defects in the lower gastrointestinal tract. The Orbera Intragastric Balloon System is a non-surgical alternative for interventional weight loss.

HQ8F Intrinsic Value
Not Available
A

See Also

What is Apollo Endosurgery Inc's Other Non-Cash Items?
Other Non-Cash Items
12.5m USD

Based on the financial report for Dec 31, 2022, Apollo Endosurgery Inc's Other Non-Cash Items amounts to 12.5m USD.

What is Apollo Endosurgery Inc's Other Non-Cash Items growth rate?
Other Non-Cash Items CAGR 5Y
40%

Over the last year, the Other Non-Cash Items growth was 100%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett